+

WO2006040688A2 - Inhibitors of acetylcholinesterase for treating skin diseases - Google Patents

Inhibitors of acetylcholinesterase for treating skin diseases Download PDF

Info

Publication number
WO2006040688A2
WO2006040688A2 PCT/IB2005/003508 IB2005003508W WO2006040688A2 WO 2006040688 A2 WO2006040688 A2 WO 2006040688A2 IB 2005003508 W IB2005003508 W IB 2005003508W WO 2006040688 A2 WO2006040688 A2 WO 2006040688A2
Authority
WO
WIPO (PCT)
Prior art keywords
group
use according
acetylcholinesterase inhibitor
treatment
atom
Prior art date
Application number
PCT/IB2005/003508
Other languages
French (fr)
Other versions
WO2006040688A3 (en
WO2006040688B1 (en
Inventor
Ernir Snorrason
Original Assignee
Ernir Snorrason
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0422634A external-priority patent/GB2419093A/en
Priority claimed from GB0504202A external-priority patent/GB0504202D0/en
Application filed by Ernir Snorrason filed Critical Ernir Snorrason
Priority to EP05805713A priority Critical patent/EP1807087A2/en
Priority to US11/665,280 priority patent/US9186345B2/en
Publication of WO2006040688A2 publication Critical patent/WO2006040688A2/en
Publication of WO2006040688A3 publication Critical patent/WO2006040688A3/en
Publication of WO2006040688B1 publication Critical patent/WO2006040688B1/en
Priority to US14/737,998 priority patent/US9730919B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics

Definitions

  • the present invention relates to a method for the topical treatment of a variety of skin diseases and skin problems.
  • the treatment of the present invention consists of the topical administration of an acetylcholinesterase inhibitor such as galantamine hydrobromide or donepezil hydrochloride.
  • an acetylcholinesterase inhibitor such as galantamine hydrobromide or donepezil hydrochloride.
  • galantamine was previously known as "galanthamine”.
  • Acetylcholine is a classical neurotransmitter that has increasingly been recognized to occur in a large variety of cells outside the central nervous system (CNS). Acetylcholine has been shown to be produced in fibroblasts, melanocytes, endothelial cells and cells of the immune system. Acetylcholine can alter a variety of cellular functions where it acts on cells through its two classes of receptors, nicotinic acetylcholine receptors and muscarinic receptors.
  • the nicotinic acetylcholine receptor is a ligand-gated ion channel formed by five subunits: alpha 3, alpha 5, beta 2 and beta 4 subunits, and by alpha 7 subunits that can form functional nicotinic receptors of their own.
  • alpha 3, alpha 5, beta 2 and beta 4 subunits alpha 7 subunits that can form functional nicotinic receptors of their own.
  • the presence of these structures, i.e. in keratocytes can be shown by histochemical methods, i.e. antibodies to alpha 3 or alpha 7 subunits.
  • the importance of acetylcholine in inflammation can also be determined by measuring the augmentation of the activity of the hydrolysing enzyme of acetylcholine, acetylcholinesterase, for instance in rheumatoid arthritis in the synovial fluid (cf.
  • Snorrason, Ernir US patent no. 6,358,941 Bl. See also US patent no 5,312,817. Snorrason, Ernir, May 14, cf. the importance of treating oedema of the CNS with these agents.).
  • acetylcholinesterases inhibitors augment Cortisol and endorphin release, (cf. Cozantis D.A. Galanthamine hydrobromide versus neostigmine: a plasma Cortisol study in man, Anaesthesia 1974;29:163-168.).
  • Galantamine augments Cortisol releasing hormone (CRH) by augmenting the cholinergic input to the hypothalamus.
  • the present invention consists in a method of treating skin diseases or problems of a mammal, which may be human, by the topical administration to the site of the disease or problem of an acetylcholinesterase inhibitor.
  • the invention also provides the use of an acetylcholinesterase inhibitor for the manufacture of a medicament for the topical treatment of skin diseases and skin problems. It should be noted that all of the indications to which the present invention applies are non-arthritic.
  • the primary use of the compounds of the present invention is expected to be for the treatment or prevention of skin diseases in humans, they may also be used to treat other animals, especially, but not exclusively, mammals, and so they may have application in veterinary medicine.
  • the accompanying drawing shows the progress of psoriasis on the hand of a 62 year old female patient over a 4 week period, as described hereafter in Example 2.
  • the skin diseases and problems to which the present invention is applicable include:
  • Adnexal Diseases Acne vulgaris, acne rosacea (rosacea), perioral dermatitis, folliculitis, hyperhidrosis, Grover's disease,
  • Rheumatologic disorders skin symptoms: Different forms of lupus erythematous, dermatomyosistis, systemic sclerosis, other rheumatologic disorder such as Sjogren's syndrome, mixed connective tissue disease and cutaneous manifestations of rheumatologic disorders, morphea, lichen sclerosus and atrophicus, panniculitis,
  • disorders due to physical agents Disorders caused by radiation, including UV light and sunburn, photodamage, disorders caused by abnormal reaction to UV light such as polymorphous light eruption, burns and diseases caused by heat or cold, chemical burns, frictional and traumatic injuries to the skin.
  • disorders and states caused by normal or abnormal aging of the skin including wrinkles. Ulcers of the skin, caused by impaired blood flow, infections, pressure, vasculitis or immunological mechanisms.
  • Urticria eythema and purpura Urticaria and angioedema, erythema multiforme, erythema annuare centrifugum and other erythmatous disorders, drug reactions of the skin, vasculitis and purpura of the skin, neutrophilic dermatoses and pregnancy dermatoses.
  • G Prevention or treatment of neoplastic disorders of the skin: Malignant melanoma, squamous cell carcinoma, basal cell carcinoma, pre-malignant disorders, benign skin tumours, actinic keratoses and premalignant conditions.
  • Alopecia areata, alopecia androgenica, hypopigmentation including vitiligo, hyperpigmentation.
  • the acetylcholinesterase inhibitor is preferably formulated with conventional diluents and excipients such as are well known for use in topical formulations.
  • the active compound is preferably formulated as a gel, cream, spray, lotion or ointment.
  • galantamine is only an example of an acetylcholinesterase inhibitor for use in the present invention, other acetylcholinesterase inhibitors may equally be used.
  • examples of such compounds include galantamine derivatives, such as those compounds of formula (I) :
  • the two symbols R* are the same as or different from each other and each represents a hydrogen atom, a hydroxy group, an alkyl group, an aryl group, an aralkyl group, a hydroxyalkyl group, a thioalkyl group, a carboxyalkyl group, a carboxyalkylamino group, an alkylamino group, an acyl group, a cyano group, a sulphhydryl group, a C j - Cg alkoxy group, an alkylthio group, an aryloxy group, an arylthio group, an aliphatic or aromatic carbamoyl group, an aralkoxy group, an aralkylthio group, an aryloxymethyl group, an alkanoyloxy group, a hydroxyalkanoyloxy group, a benzoyloxy group, a benzoyloxy group substituted by one or more groups R- ⁇ 5 as defined below, or an aryl
  • R ⁇ represents a hydrogen atom, a C ⁇ - Cg alkyl group, a C2 - Cg alkenyl group (e.g. an allyl group), an aralkyl group, said alkyl, alkenyl and aralkyl groups being unsubstituted or being substituted by at least one halogen atom, a cycloalkyl group, a hydroxy group, an alkoxy group, a nitro group, an amino group, an aminoalkyl group, an acylamino group, an aromatic or non-aromatic heterocyclic group (e.g.
  • an ⁇ - or ⁇ - furyl group an ⁇ - or ⁇ - thienyl group, an ⁇ - or ⁇ - thenyl group, a pyridyl group, a pyrazinyl group, or a pyrimidyl group
  • an alkyl group substituted by an aromatic heterocyclic group an aryl group (e.g. a phenyl group), an aralkyl group, a cyano group, an aroyl group, or a cycloalkylmethyl group
  • Rr are the same as or different from each other and each represents a hydrogen atom, a hydroxy group, an alkyl group, an aryl group, an aralkyl group, a hydroxyalkyl group, a thioalkyl group, a sulphhydryl group, a C ⁇ - Cg alkoxy group, an aryloxy group, an arylthio group, an aralkoxy group, an aralkylthio group, a nitro group, an amino group, an alkylamino group, an arylamino group, an aralkylamino group, a halogen atom or a trifluoromethyl group;
  • R7 are the same as or different from each other and each represents a hydrogen atom, a halogen atom, a trifluoromethyl group, or a C ⁇ - C4 alkyl group;
  • R" represents a hydrogen atom or a C ⁇ - Cg alkyl group, or, when the symbol Re ⁇
  • R" represents a group of formula (Ia) :
  • R a represents a linking bond
  • R 1 , R 2 , R ⁇ , R ⁇ R 5 , X and Y are as defined for formula (I); or R6 and the symbol R ⁇ attached to the same carbon atom as R" together represent a semicarbazone;
  • X represents an oxygen atom or a group of formula -NR ⁇ , where R ⁇ is as defined above;
  • Y represents a nitrogen atom or a phosphorus atom
  • alkyl groups may be straight or branched chain and preferably have from 1 to 10 carbon atoms, and examples of these include the methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, t-butyl, pentyl, hexyl, heptyl, octyl, nonyl and decyl groups.
  • Alkoxy groups and other simple derivatives of the alkyl groups likewise preferably have from 1 to 10, more preferably from 1 to 6, carbon atoms.
  • Aryl and heterocyclic groups may be unsubstituted or they may be substituted by one or more substituents selected from the groups and atoms defined for R ⁇ , provided that any R ⁇ substituent may not itself be further substituted by a substituted aryl or heterocyclic group.
  • Preferred halogen atoms are the fluorine, chlorine, bromine and iodine atoms.
  • Preferred compounds of formula (I) are those in which the alkyl groups contain from 1 to 8, more preferably from 1 to 6, carbon atoms, halogen atoms are fluorine, chlorine or bromine atoms, aryl groups are the phenyl group (which may be substituted or unsubstituted, preferably unsubstituted), cycloalkyl groups contain from 3 to 7 ring carbon atoms (preferably cyclopropyl or cyclobutyl), acyl groups are lower (e.g. C2 - Cg alkanoyl groups) and heterocyclic groups are aromatic and contain from 5 to 8 ring atoms (e.g. the thienyl, furyl, pyridyl, pyrrolyl or pyrazinyl groups).
  • Particularly preferred compounds for use in the present invention are those compounds of formula (II):
  • R* a and R ⁇ a are the same as or different from each other and each represents a hydrogen atom, an acyl group (preferably a lower alkanoyl group, such as an acetyl group) or a C j - Cg alkyl group (such as a methyl, ethyl, propyl or isopropyl group);
  • an acyl group preferably a lower alkanoyl group, such as an acetyl group
  • a C j - Cg alkyl group such as a methyl, ethyl, propyl or isopropyl group
  • R ⁇ a represents an alkyl, alkenyl or aralkyl group, any of which may be unsubstituted or substituted by one or more halogen atoms, or it represents a cycloalkyl, hydroxy, alkoxy, nitro, amino, aminoalkyl, acylamino, aromatic heterocyclic, aroyl, aroylalkyl or cyano group; and
  • R ⁇ a represents a hydrogen or halogen atom
  • galantamine and its salts or donepezil and its salts especially the halides, such as galantamine hydrobromide or donepezil hydrochloride.
  • Galantamine derivatives which may be used in the present invention include norgalantamine, norgalantamine derivatives and epigalantamine.
  • acetylcholinesterase inhibitor examples include: physostigmine, tacrine and tacrine analogues, fasciculin, metrifonate, heptyl- physostigmine, norpyridostigmine, norneostigmine, neostigmine, pyridostigmine, huperzine or a prodrug therefor, rivastigmine or a prodrug therefor, gossypol or phenserine, or a prodrug therefor.
  • acetylcholinesterase inhibitor is donepezil and its salts, especially the halides, such as donepezil hydrochloride.
  • the compounds of the present invention are applied topically to the site of the skin trauma, disease or disorder or other problem.
  • they are preferably formulated in a suitable form for topical administration, especially gel, cream, spray, lotion or ointment.
  • the formulations used in the present invention comprise the active compound, the acetylcholinesterase inhibitor, in admixture with one or more acceptable carriers and optionally other therapeutic ingredients.
  • the carrier(s) must be acceptable in the sense that they should be compatible with the other ingredients of the formulation and not deleterious to the patient.
  • acetylcholinesterase inhibitor in the formulation, the amount depending on the dose of the active compound which it is desired should be applied.
  • a formulation administered to the site of a lesion and containing the acetylcholinesterase inhibitors of the present invention has a minimal systemic effect because of the low blood concentration when these agents are applied topically.
  • a concentration of the active ingredient ranging from 0.05 to 2% by weight is usually preferred, an amount from 0.005 to 1% of the total weight of the topical formulation being most preferred.
  • the topical agent is preferably water-based. It may contain other conventional additives, for example emulsifying agents such as hydroxymethyl cellulose, hydroxypropylmethyl cellulose, and stabilisers such as polyvinylpyrrolidone.
  • the acetylcholinesterase inhibitor may also be applied to a wound, lesion, trauma or other skin disorder on a wound dressing, such as a plaster, band-aid or the like.
  • nicotinic acetylcholine receptor found on the surface of macrophages leads to inhibition of the release of tumour necrosis factor (TNF) from macrophages and thus could control various inflammatory states of the skin. It has also been observed that pain and pruritus decrease.
  • TNF tumour necrosis factor
  • the prototype medication used here as cholinesterase inhibitors are galantamine hydrobromide and donepezil hydrochloride (also called E2020, empirical formula C24H29NO.3HCI, also called aricept).
  • the gel used was of the following composition:
  • HPMC hydroxypropyl methyl cellulose
  • PVP-40 polyvinylpyrrolidone
  • Psoriasis is a hyperproliferative disease with altered differentiation of the keratinocytes.
  • the keratinocytes in psoriatic skin lesions have an increase in the rate of maturation and it takes 3 to 4 days for a psoriatic basal cell to reach the horny layer, compared with the normal 3-4 weeks.
  • the lesions in these patients were all symmetric and each patient was treated with the formulation of the present invention without the active compound on one side and with the active compound on the other. Each patient was treated as his own control (simple blind).
  • the treatment consisted of applying a gel containing 0.1% of the active compound for two days twice daily and then switching to the ointment containing 1% of the active compound as no adverse effect was noticed.
  • Two patients were treated with galantamine and three patients with donepezil.
  • the treatment was also carried out in a group of people with severe sunburn where it controlled pain, erythema and itching.
  • the patient was a 62 year old woman with plaque psoriasis, who showed a dramatic regression of skin lesions following therapy with 0.5% topical donepezil hydrochloride cream (TDH).
  • TSH topical donepezil hydrochloride cream
  • the patient's progress over a 4 week period is shown in the accompanying drawing.
  • the first part of this drawing shows the hand of the patient at presentation before starting treatment with TDH.
  • the patient had thick psoriasis plaques at the dorsal area of the hands, elbows and knees and lesions in intertigenous areas.
  • the lesions were slightly itchy and, except in the intertrigenous areas, they were covered with silvery scales.
  • psoriasis The pathogenesis of psoriasis is still not completely understood.
  • psoriasis was considered to be mainly an epidermal disease, but various systemic abnormalities have been demonstrated in relation to inflammation and immune function.
  • the T-lymphocyte is the predominant cell in the psoriatic infiltrate and ciclosporin and the newer biologic therapies all have an effect on the T-cell response and have been shown to be effective in the treatment of psoriasis.
  • the extraneuronal cholinergic system is involved in regulating several functions of the skin independent of neuronal innervation. It has been shown that keratinocytes and melanocytes synthesize acetylcholine. Acetylcholine acts via two major signals, the nicotinic and muscarinic receptors. The cholinergic system has been thought to be involved in the apoptosis that occurs when keratinocytes differentiate from stratum granulosum to stratum coreneum. Furthermore the extraneuronal cholinergic system is involved in microcirculation, terminal differentiation of the skin, sweat and sebum secretion and barrier formation.
  • keratinocytes have nicotinic and muscarinic receptors that have an important role in the normal life cycle of the skin. Additionally it has been demonstrated that keratinocyte adhesion is controlled by acetylcholine. Also it has been demonstrated that acetylcholine in vitro stimulates keratinocyte growth and spreading, and is thus likely to promote re-epithelization of the skin in wound healing.
  • the muscarinic receptors on skin fibroblasts, keratinocytes and melanocytes have five subtypes and lead either to inhibition of cAMP or regulate intracellular calcium levels. The exact role of these receptors still remains to be elucidated, but they have been implemented in control of melano genesis amongst other functions.
  • the nicotinic receptors have a different molecular construction and even these receptors have several molecular subtypes.
  • the nicotinic receptors form ion channels that gate either sodium, potassium or calcium. It has been postulated that the nicotinic receptor plays a central role in terminal differentiation and barrier formation of the epidermis.
  • acetylcholine in inflammatory states has been demonstrated by increased activity of the hydrolysing enzyme of acetylcholine, acetylcholinesterase, in the synovial fluid of patients with rheumatoid arthritis.
  • acetylcholine is an important molecule that controls several important functions of the skin. It is possible that inflammation in the psoriasis lesions, similarly as has been described in patients with rheumatoid arthritis, leads to decreased amounts of acetylcholine in the skin and thus decreased keratinocyte adhesion and loss of control of keratinocyte differentiation. By applying TDH to the skin normal levels of acetylcholine are restored and keratinocyte homeostasis is brought back to normal, and thus reversing the pathology in the psoriasis lesions.
  • tumour necrosis factor plays an important role in both plaque psoriasis and psoriatic arthritis and that drugs that inhibit TNF can control both the skin and arthritic symptoms. It is therefore possible that, via the nicotinic acetylcholine receptor found on the surface of macrophages, there is inhibition of the release of tumour necrosis factor (TNF) from macrophages and this could control the inflammatory state in the psoriasis lesions.
  • TNF tumour necrosis factor
  • Donepezil hydrochloride has been shown to be a safe molecule in several studies on Alzheimer's disease where the drug is used orally. It is likely that site effects are even less when used topically. In the patients described above no site effects were seen. We therefore believe that the cholinergic system in the skin is a novel pharmacological target and that topical acetylcholine inhibitors might become important topical drugs in the treatment of skin diseases. We believe this case demonstrates that the extraneural cholinergic system might be involved in the pathogenesis of psoriasis and that it merits further research on the extraneural cholinergic system in health and diseases states of the skin.

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Acetylcholinesterase inhibitors, such as galantamine or donepezil, have been found to be useful in the topical treatment of skin diseases and skin problems.

Description

METHOD OF TREATING SKIN DISEASES
The present invention relates to a method for the topical treatment of a variety of skin diseases and skin problems.
The treatment of the present invention consists of the topical administration of an acetylcholinesterase inhibitor such as galantamine hydrobromide or donepezil hydrochloride. It should be noted that the compound here referred to as "galantamine" was previously known as "galanthamine". These agents inhibit the hydrolysis of the transmitter acetylcholine which is located in the interstitial fluid or presynaptic cleft. It is postulated that the hydrolysis of acetylcholine is augmented in oedema and various inflammatory states of the skin. Also it has been shown that the nicotinic receptor is involved in the control of calcium influx into cells and different immune reactions involved in inflammation and trauma.
It has been shown (cf. "A nicotinic acetylcholine receptor regulating cell adhesion and motility is expressed in human keratinocytes" Grando SA et al. J. Invest. Dermatol, 105:6.6 1995 December, 774-81) that keratinocytes have nicotinic and muscarinic receptors that have an important role in the normal life cycle of the skin.
Acetylcholine is a classical neurotransmitter that has increasingly been recognized to occur in a large variety of cells outside the central nervous system (CNS). Acetylcholine has been shown to be produced in fibroblasts, melanocytes, endothelial cells and cells of the immune system. Acetylcholine can alter a variety of cellular functions where it acts on cells through its two classes of receptors, nicotinic acetylcholine receptors and muscarinic receptors. The nicotinic acetylcholine receptor is a ligand-gated ion channel formed by five subunits: alpha 3, alpha 5, beta 2 and beta 4 subunits, and by alpha 7 subunits that can form functional nicotinic receptors of their own. The presence of these structures, i.e. in keratocytes, can be shown by histochemical methods, i.e. antibodies to alpha 3 or alpha 7 subunits. The importance of acetylcholine in inflammation can also be determined by measuring the augmentation of the activity of the hydrolysing enzyme of acetylcholine, acetylcholinesterase, for instance in rheumatoid arthritis in the synovial fluid (cf. Snorrason, Ernir: US patent no. 6,358,941 Bl. See also US patent no 5,312,817. Snorrason, Ernir, May 14, cf. the importance of treating oedema of the CNS with these agents.). In this context it should be noted that acetylcholinesterases inhibitors augment Cortisol and endorphin release, (cf. Cozantis D.A. Galanthamine hydrobromide versus neostigmine: a plasma Cortisol study in man, Anaesthesia 1974;29:163-168.). Galantamine augments Cortisol releasing hormone (CRH) by augmenting the cholinergic input to the hypothalamus. It has also been shown that galantamine augments endorphin release ( cf. Cozantis, op. cit.). Recently it has been demonstrated that the nicotinic acetylcholine receptor α7 subunit is found on the surface of macrophages and that stimulation of this receptor leads to inhibition of the release of tumour necrosis factor (TNF) from macrophages and thus could control various inflammatory states of the skin (Wang, H., M. Yu, M. Ochani, C. A. Amelia, M.
Tanovic, S. Susarla, J. H. Li, H. Wang, H. Yang, L. Ulloa, Y. Al- Abed, C. J. Czura, and K. J. Tracey. "Nicotinic Acetylcholine Receptor Alpha7 Subunit Is an Essential Regulator of Inflammation." Nature 421, no. 6921 (2003): 384-8.)
I have now surprisingly found that skin problems can be treated locally by the topical application of one or more acetylcholinesterase inhibitors and that the main action in pathological states of the skin is local to keratocytes and other skin cells. This can be shown by administering topical agents containing acetylcholinesterase inhibitors (e.g. creams) directly to the skin lesions.
Thus, the present invention consists in a method of treating skin diseases or problems of a mammal, which may be human, by the topical administration to the site of the disease or problem of an acetylcholinesterase inhibitor.
The invention also provides the use of an acetylcholinesterase inhibitor for the manufacture of a medicament for the topical treatment of skin diseases and skin problems. It should be noted that all of the indications to which the present invention applies are non-arthritic.
Although the primary use of the compounds of the present invention is expected to be for the treatment or prevention of skin diseases in humans, they may also be used to treat other animals, especially, but not exclusively, mammals, and so they may have application in veterinary medicine.
The accompanying drawing shows the progress of psoriasis on the hand of a 62 year old female patient over a 4 week period, as described hereafter in Example 2.
The skin diseases and problems to which the present invention is applicable include:
A. Papulosquamous and Eczematous Dermatoses. Psoriasis, pityriasis rosea, pityriasis rubra pilaris, pityriasis lichenoides et varioliformis acuta and chronica, parapsoriasis group of disorders, erythoderma, lichen planus and lichenoid disorders, atopic dermatitis, allergic contact dermatitis, irritant contact dermatitis, other eczematous disorders such as seborrhoeic dermatitis and other eczematous disorders.
B. Vesiculobullous Diseases: Pemphigus, pemphigoid, dermatitis herpetiformis, epidermalysis bullosa, linear IgA dermatosis and other bullous disorders
C. Adnexal Diseases: Acne vulgaris, acne rosacea (rosacea), perioral dermatitis, folliculitis, hyperhidrosis, Grover's disease,
D. Rheumatologic disorders (skin symptoms): Different forms of lupus erythematous, dermatomyosistis, systemic sclerosis, other rheumatologic disorder such as Sjogren's syndrome, mixed connective tissue disease and cutaneous manifestations of rheumatologic disorders, morphea, lichen sclerosus and atrophicus, panniculitis,
E. Disorders due to physical agents: Disorders caused by radiation, including UV light and sunburn, photodamage, disorders caused by abnormal reaction to UV light such as polymorphous light eruption, burns and diseases caused by heat or cold, chemical burns, frictional and traumatic injuries to the skin. Disorders and states caused by normal or abnormal aging of the skin including wrinkles. Ulcers of the skin, caused by impaired blood flow, infections, pressure, vasculitis or immunological mechanisms.
F. Urticria eythema and purpura: Urticaria and angioedema, erythema multiforme, erythema annuare centrifugum and other erythmatous disorders, drug reactions of the skin, vasculitis and purpura of the skin, neutrophilic dermatoses and pregnancy dermatoses.
G. Prevention or treatment of neoplastic disorders of the skin: Malignant melanoma, squamous cell carcinoma, basal cell carcinoma, pre-malignant disorders, benign skin tumours, actinic keratoses and premalignant conditions.
H. Other disorders, signs or symptoms of the skin: Pruritus, neuralgia, abnormal sensation or pain states, such has burning, oedema of the skin.
Alopecia areata, alopecia androgenica, hypopigmentation including vitiligo, hyperpigmentation.
The acetylcholinesterase inhibitor is preferably formulated with conventional diluents and excipients such as are well known for use in topical formulations. The active compound is preferably formulated as a gel, cream, spray, lotion or ointment.
Although galantamine is only an example of an acetylcholinesterase inhibitor for use in the present invention, other acetylcholinesterase inhibitors may equally be used. Examples of such compounds include galantamine derivatives, such as those compounds of formula (I) :
Figure imgf000006_0001
in which:
the dotted line indicates that there is a single or double carbon-carbon bond;
the two symbols R* are the same as or different from each other and each represents a hydrogen atom, a hydroxy group, an alkyl group, an aryl group, an aralkyl group, a hydroxyalkyl group, a thioalkyl group, a carboxyalkyl group, a carboxyalkylamino group, an alkylamino group, an acyl group, a cyano group, a sulphhydryl group, a Cj - Cg alkoxy group, an alkylthio group, an aryloxy group, an arylthio group, an aliphatic or aromatic carbamoyl group, an aralkoxy group, an aralkylthio group, an aryloxymethyl group, an alkanoyloxy group, a hydroxyalkanoyloxy group, a benzoyloxy group, a benzoyloxy group substituted by one or more groups R-^5 as defined below, or an aryloxycarbonyl group;
R^ represents a hydrogen atom, a C^ - Cg alkyl group, a C2 - Cg alkenyl group (e.g. an allyl group), an aralkyl group, said alkyl, alkenyl and aralkyl groups being unsubstituted or being substituted by at least one halogen atom, a cycloalkyl group, a hydroxy group, an alkoxy group, a nitro group, an amino group, an aminoalkyl group, an acylamino group, an aromatic or non-aromatic heterocyclic group (e.g. an α- or β- furyl group, an α- or β- thienyl group, an α- or β- thenyl group, a pyridyl group, a pyrazinyl group, or a pyrimidyl group), an alkyl group substituted by an aromatic heterocyclic group, an aryl group (e.g. a phenyl group), an aralkyl group, a cyano group, an aroyl group, or a cycloalkylmethyl group;
the symbols Rr are the same as or different from each other and each represents a hydrogen atom, a hydroxy group, an alkyl group, an aryl group, an aralkyl group, a hydroxyalkyl group, a thioalkyl group, a sulphhydryl group, a C^ - Cg alkoxy group, an aryloxy group, an arylthio group, an aralkoxy group, an aralkylthio group, a nitro group, an amino group, an alkylamino group, an arylamino group, an aralkylamino group, a halogen atom or a trifluoromethyl group;
the symbols R7 are the same as or different from each other and each represents a hydrogen atom, a halogen atom, a trifluoromethyl group, or a C^ - C4 alkyl group;
the two symbols R? are the same as or different from each other and each represents a hydrogen atom, or a hydroxymethyl group;
R" represents a hydrogen atom or a C^ - Cg alkyl group, or, when the symbol Re¬
attached to the same carbon atom as R" represents a hydrogen atom, R" represents a group of formula (Ia) :
Figure imgf000007_0001
where Ra represents a linking bond, and R1, R2, R^, R^ R5, X and Y are as defined for formula (I); or R6 and the symbol R^ attached to the same carbon atom as R" together represent a semicarbazone;
X represents an oxygen atom or a group of formula -NR^, where R^ is as defined above;
Y represents a nitrogen atom or a phosphorus atom;
and pharmaceutically acceptable salts thereof.
hi the compounds of formula (I) above, except where otherwise indicated, alkyl groups may be straight or branched chain and preferably have from 1 to 10 carbon atoms, and examples of these include the methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, t-butyl, pentyl, hexyl, heptyl, octyl, nonyl and decyl groups. Alkoxy groups and other simple derivatives of the alkyl groups likewise preferably have from 1 to 10, more preferably from 1 to 6, carbon atoms.
Aryl and heterocyclic groups may be unsubstituted or they may be substituted by one or more substituents selected from the groups and atoms defined for R^, provided that any R^ substituent may not itself be further substituted by a substituted aryl or heterocyclic group.
Preferred halogen atoms are the fluorine, chlorine, bromine and iodine atoms.
Preferred compounds of formula (I) are those in which the alkyl groups contain from 1 to 8, more preferably from 1 to 6, carbon atoms, halogen atoms are fluorine, chlorine or bromine atoms, aryl groups are the phenyl group (which may be substituted or unsubstituted, preferably unsubstituted), cycloalkyl groups contain from 3 to 7 ring carbon atoms (preferably cyclopropyl or cyclobutyl), acyl groups are lower (e.g. C2 - Cg alkanoyl groups) and heterocyclic groups are aromatic and contain from 5 to 8 ring atoms (e.g. the thienyl, furyl, pyridyl, pyrrolyl or pyrazinyl groups).
Particularly preferred compounds for use in the present invention are those compounds of formula (II):
Figure imgf000009_0001
where:
R*a and R^a are the same as or different from each other and each represents a hydrogen atom, an acyl group (preferably a lower alkanoyl group, such as an acetyl group) or a C j - Cg alkyl group (such as a methyl, ethyl, propyl or isopropyl group);
R^ a represents an alkyl, alkenyl or aralkyl group, any of which may be unsubstituted or substituted by one or more halogen atoms, or it represents a cycloalkyl, hydroxy, alkoxy, nitro, amino, aminoalkyl, acylamino, aromatic heterocyclic, aroyl, aroylalkyl or cyano group; and
R^a represents a hydrogen or halogen atom;
and pharmaceutically acceptable salts thereof, especially the hydrobromide, hydrochloride, methylsulphonate or methiodide.
Of these compounds, we particularly prefer galantamine and its salts or donepezil and its salts, especially the halides, such as galantamine hydrobromide or donepezil hydrochloride.
Galantamine derivatives which may be used in the present invention include norgalantamine, norgalantamine derivatives and epigalantamine.
Other compounds which may be used as the acetylcholinesterase inhibitor include: physostigmine, tacrine and tacrine analogues, fasciculin, metrifonate, heptyl- physostigmine, norpyridostigmine, norneostigmine, neostigmine, pyridostigmine, huperzine or a prodrug therefor, rivastigmine or a prodrug therefor, gossypol or phenserine, or a prodrug therefor.
Another particularly preferred acetylcholinesterase inhibitor is donepezil and its salts, especially the halides, such as donepezil hydrochloride.
The compounds of the present invention are applied topically to the site of the skin trauma, disease or disorder or other problem. To facilitate this, they are preferably formulated in a suitable form for topical administration, especially gel, cream, spray, lotion or ointment. Thus, the formulations used in the present invention comprise the active compound, the acetylcholinesterase inhibitor, in admixture with one or more acceptable carriers and optionally other therapeutic ingredients. The carrier(s) must be acceptable in the sense that they should be compatible with the other ingredients of the formulation and not deleterious to the patient.
There is no particular restriction on the content of the acetylcholinesterase inhibitor in the formulation, the amount depending on the dose of the active compound which it is desired should be applied. However, a formulation administered to the site of a lesion and containing the acetylcholinesterase inhibitors of the present invention has a minimal systemic effect because of the low blood concentration when these agents are applied topically. A concentration of the active ingredient ranging from 0.05 to 2% by weight is usually preferred, an amount from 0.005 to 1% of the total weight of the topical formulation being most preferred.
The topical agent is preferably water-based. It may contain other conventional additives, for example emulsifying agents such as hydroxymethyl cellulose, hydroxypropylmethyl cellulose, and stabilisers such as polyvinylpyrrolidone.
Other conventional additives may be included, as is well known to those skilled in the art.
The acetylcholinesterase inhibitor may also be applied to a wound, lesion, trauma or other skin disorder on a wound dressing, such as a plaster, band-aid or the like. CLINICAL TESTS
Clinical testing with ointments containing acetylcholinesterase inhibitors has been started in the following clinical entities: psoriasis, inflammation because of trauma, atopic dermatitis, wound healing, sun burn and wrinkles. The basic assumption is that topical agents containing acetylcholinesterase inhibitors influence the normal cycle of the renewal of the skin and improve this process in pathological states. Also it is thought to decrease local oedema by favouring the influx of calcium from the interstitial fluid, thereby restoring the normal fluid balance in local lesions of various kinds where oedema is one of the symptoms. It is also possible that the nicotinic acetylcholine receptor found on the surface of macrophages leads to inhibition of the release of tumour necrosis factor (TNF) from macrophages and thus could control various inflammatory states of the skin. It has also been observed that pain and pruritus decrease.
The prototype medication used here as cholinesterase inhibitors are galantamine hydrobromide and donepezil hydrochloride (also called E2020, empirical formula C24H29NO.3HCI, also called aricept).
EXAMPLE 1
The gel used was of the following composition:
HPMC (hydroxypropyl methyl cellulose) 3%
PVP-40 (polyvinylpyrrolidone) 1%
Donepezil HCl or Galantamine HBr 0.1 or 1.0 %
H2O balance
Patients for the treatment of psoriasis(five patients) were chosen as having a relatively secure diagnosis of plaque type psoriasis vulgaris with silvery scales covering the surface of the lesion.. This disease tends to be chronic, and often difficult to treat with topical agents. AU of the five patients treated were diagnosed by a dermatologist and had the diagnosis for over three years. None of these patients had arthritis. Psoriasis is a hyperproliferative disease with altered differentiation of the keratinocytes. The keratinocytes in psoriatic skin lesions have an increase in the rate of maturation and it takes 3 to 4 days for a psoriatic basal cell to reach the horny layer, compared with the normal 3-4 weeks.
After a treatment, which may vary from two weeks to one month, there was a considerable improvement both scaling, size, thickness and erythematous appearance of the lesions. The lesions in these patients were all symmetric and each patient was treated with the formulation of the present invention without the active compound on one side and with the active compound on the other. Each patient was treated as his own control (simple blind).
In one patient, a lesion which had been present for three years almost disappeared after treatment for one month. Pruritus had been present in all the patients but with varying severity. AU of the patients reported an absence of itching during the treatment.
The treatment consisted of applying a gel containing 0.1% of the active compound for two days twice daily and then switching to the ointment containing 1% of the active compound as no adverse effect was noticed. Two patients were treated with galantamine and three patients with donepezil.
Similar trials were carried out in wrinkles, where 12 women between fifty and sixty years of age were treated once a day three times a week for eight weeks. All patients reported improvement in skin texture and reduction of fine lines and this view was shared by their dermatologist. The women reported that the results achieved were comparable with or better than more expensive skin treatments of various sorts.
In wound healing, two patients who had chronic ulcers or wounds that did not heal became considerably better after treatment for four weeks.
The treatment was also carried out in a group of people with severe sunburn where it controlled pain, erythema and itching.
There are indications that this kind of treatment lessens oedema produced by trauma, and is especially fast in the acute phase of the inflammation. EXAMPLE 2
The patient was a 62 year old woman with plaque psoriasis, who showed a dramatic regression of skin lesions following therapy with 0.5% topical donepezil hydrochloride cream (TDH).
The clinical diagnosis of psoriasis had been made at the age of 58. At that time, the patient had typical psoriasis plaques at the knees and elbows. She had previously been treated with topical agents, both corticosteroids and salicylic acid. This treatment gave partial remission of psoriatic lesions, but complete remission was never achieved. As the patient did not want to take oral medications and because she was no longer responsive to topical therapy, the patient elected to continue only with moisturizers.
Thus, prior to the current treatment with TDH the patient had only used moisturizers for the last three years. During this time her lesions were stable.
The patient's progress over a 4 week period is shown in the accompanying drawing. The first part of this drawing shows the hand of the patient at presentation before starting treatment with TDH. At this time, the patient had thick psoriasis plaques at the dorsal area of the hands, elbows and knees and lesions in intertigenous areas. The lesions were slightly itchy and, except in the intertrigenous areas, they were covered with silvery scales.
The patient started treatment with 0.5% THD cream b.i.d. The patient noted after 2 days of therapy that the itching stopped. After seven days (drawing part 2), the scales had disappeared, infiltration could still be detected, but lesions were considerably thinner. After three weeks (drawing part 3), the lesions had almost disappeared, infiltration could not be detected, but some residual erythema could still be seen. After four weeks of treatment (drawing part 4), all lesions had completely disappeared. The patient continued treatment for a further two weeks after the symptoms had disappeared. At four weeks after stopping treatment, there was still no sign of reappearance of the psoriasis lesions. The treatment was well tolerated with no local or systemic side effects.
The pathogenesis of psoriasis is still not completely understood. For many years psoriasis was considered to be mainly an epidermal disease, but various systemic abnormalities have been demonstrated in relation to inflammation and immune function. The T-lymphocyte is the predominant cell in the psoriatic infiltrate and ciclosporin and the newer biologic therapies all have an effect on the T-cell response and have been shown to be effective in the treatment of psoriasis.
There is evidence that the extraneuronal cholinergic system is involved in regulating several functions of the skin independent of neuronal innervation. It has been shown that keratinocytes and melanocytes synthesize acetylcholine. Acetylcholine acts via two major signals, the nicotinic and muscarinic receptors. The cholinergic system has been thought to be involved in the apoptosis that occurs when keratinocytes differentiate from stratum granulosum to stratum coreneum. Furthermore the extraneuronal cholinergic system is involved in microcirculation, terminal differentiation of the skin, sweat and sebum secretion and barrier formation.
It has been shown that keratinocytes have nicotinic and muscarinic receptors that have an important role in the normal life cycle of the skin. Additionally it has been demonstrated that keratinocyte adhesion is controlled by acetylcholine. Also it has been demonstrated that acetylcholine in vitro stimulates keratinocyte growth and spreading, and is thus likely to promote re-epithelization of the skin in wound healing.
The muscarinic receptors on skin fibroblasts, keratinocytes and melanocytes have five subtypes and lead either to inhibition of cAMP or regulate intracellular calcium levels. The exact role of these receptors still remains to be elucidated, but they have been implemented in control of melano genesis amongst other functions. The nicotinic receptors have a different molecular construction and even these receptors have several molecular subtypes. The nicotinic receptors form ion channels that gate either sodium, potassium or calcium. It has been postulated that the nicotinic receptor plays a central role in terminal differentiation and barrier formation of the epidermis.
The importance of acetylcholine in inflammatory states has been demonstrated by increased activity of the hydrolysing enzyme of acetylcholine, acetylcholinesterase, in the synovial fluid of patients with rheumatoid arthritis.
Thus it has been demonstrated that acetylcholine is an important molecule that controls several important functions of the skin. It is possible that inflammation in the psoriasis lesions, similarly as has been described in patients with rheumatoid arthritis, leads to decreased amounts of acetylcholine in the skin and thus decreased keratinocyte adhesion and loss of control of keratinocyte differentiation. By applying TDH to the skin normal levels of acetylcholine are restored and keratinocyte homeostasis is brought back to normal, and thus reversing the pathology in the psoriasis lesions. It has recently been demonstrated that tumour necrosis factor plays an important role in both plaque psoriasis and psoriatic arthritis and that drugs that inhibit TNF can control both the skin and arthritic symptoms. It is therefore possible that, via the nicotinic acetylcholine receptor found on the surface of macrophages, there is inhibition of the release of tumour necrosis factor (TNF) from macrophages and this could control the inflammatory state in the psoriasis lesions.
Donepezil hydrochloride has been shown to be a safe molecule in several studies on Alzheimer's disease where the drug is used orally. It is likely that site effects are even less when used topically. In the patients described above no site effects were seen. We therefore believe that the cholinergic system in the skin is a novel pharmacological target and that topical acetylcholine inhibitors might become important topical drugs in the treatment of skin diseases. We believe this case demonstrates that the extraneural cholinergic system might be involved in the pathogenesis of psoriasis and that it merits further research on the extraneural cholinergic system in health and diseases states of the skin.

Claims

CLAIMS:
1. The use of an acetylcholinesterase inhibitor for the manufacture of a medicament for the topical treatment of skin diseases or skin problems.
2. The use according to Claim 1, in which the disease or problem is a consequence of psoriasis.
3. The use according to Claim 1, in which the psoriasis is psoriasis vulgaris or associated with HIV infection.
4. The use according to Claim 1, in which the treatment is for palmoplantal pustules.
5. The use according to Claim 1, in which the treatment is for sunburn.
6. The use according to Claim 1, in which the treatment is for wound healing.
7. The use according to Claim 1, in which the treatment is for acne vulgaris, phemphingus vulgaris, or atopic dermatitis.
8. The use according to Claim 1, in which the treatment is for wrinkles, burn or sunburn.
9. The use according to any one of the preceding Claims, in which the acetylcholinesterase inhibitor is administered as a gel or cream.
10. The use according to any one of the preceding Claims, in which the acetylcholinesterase inhibitor is a compound of formula (I):
Figure imgf000017_0001
in which:
the dotted line indicates that there is a single or double carbon-carbon bond;
the two symbols R* are the same as or different from each other and each represents a hydrogen atom, a hydroxy group, an alkyl group, an aryl group, an aralkyl group, a hydroxyalkyl group, a thioalkyl group, a carboxyalkyl group, a carboxyalkylamino group, an alkylamino group, an acyl group, a cyano group, a sulphhydryl group, a C^ - Cg alkoxy group, an alkylthio group, an aryloxy group, an arylthio group, an aliphatic or aromatic carbamoyl group, an aralkoxy group, an aralkylthio group, an aryloxymethyl group, an alkanoyloxy group, a hydroxyalkanoyloxy group, a benzoyloxy group, a benzoyloxy group substituted by one or more groups R , as defined below, or an aryloxycarbonyl group;
R^ represents a hydrogen atom, a C i - Cg alkyl group, a C2 - Cg alkenyl group (e.g. an allyl group), an aralkyl group, said alkyl, alkenyl and aralkyl groups being unsubstituted or being substituted by at least one halogen atom, a cycloalkyl group, a hydroxy group, an alkoxy group, a nitro group, an amino group, an aminoalkyl group, an acylamino group, an aromatic or non-aromatic heterocyclic group (e.g. an α- or β- furyl group, an α- or β- thienyl group, an α- or β- thenyl group, a pyridyl group, a pyrazinyl group, or a pyrimidyl group), an alkyl group substituted by an aromatic heterocyclic group, an aryl group (e.g. a phenyl group), an aralkyl group, a cyano group, an aroyl group, or a cycloalkylmethyl group;
the symbols R^ are the same as or different from each other and each represents a hydrogen atom, a hydroxy group, an alkyl group, an aryl group, an aralkyl group, a hydroxyalkyl group, a thioalkyl group, a sulphhydryl group, a C i - Cg alkoxy group, an aryloxy group, an arylthio group, an aralkoxy group, an aralkylthio group, a nitro group, an amino group, an alkylamino group, an arylamino group, an aralkylamino group, a halogen atom or a trifluoromethyl group;
the symbols R^ are the same as or different from each other and each represents a hydrogen atom, a halogen atom, a trifluoromethyl group, or a C^ - C4 alkyl group;
the two symbols R^ are the same as or different from each other and each represents a hydrogen atom, or a hydroxymethyl group;
R" represents a hydrogen atom or a Cj - Cg alkyl group, or, when the symbol R^
attached to the same carbon atom as R° represents a hydrogen atom, R° represents a group of formula (Ia):
Figure imgf000018_0001
where Ra represents a linking bond, and R^, R^, R^, R^, R , X and Y are as defined for formula (I); or R6 and the symbol R* attached to the same carbon atom as R^ together represent a semicarbazone;
X represents an oxygen atom or a group of formula -NR^, where R^ is as defined above;
Y represents a nitrogen atom or a phosphorus atom;
or a pharmaceutically acceptable salt thereof.
11. The use according to any one of Claims 1 to 9, in which the acetylcholinesterase inhibitor is galantamine or an acetylcholinesterase inhibitory galantamine derivative, or a salt or prodrug thereof.
12. The use according to Claim 11, in which said galantamine derivative is norgalantamine, a norgalantamine derivative or epigalantamine.
13. The use according to any one of Claims 1 to 9, in which the acetylcholinesterase inhibitor is physostigmine, tacrine, a tacrine analogue, fasciculin, metrifonate, heptyl- physostigmine, norpyridostigmine, norneostigmine, neostigmine, pyridostigmine, huperzine, or rivastigmine.
14. The use according to any one of Claims 1 to 9, in which the acetylcholinesterase inhibitor is donepezil or a salt thereof.
15. The use according to Claim 14, in which the acetylcholinesterase inhibitor is donepezil hydrochloride.
16. The use according to Claim 11, in which the acetylcholinesterase inhibitor is galantamine or galantamine hydrobromide.
17. A pharmaceutically acceptable formulation in the form of a gel, ointment, spray, lotion or cream containing an acetylcholinesterase inhibitor as the active component.
18. A formulation according to Claim 17, in which the acetylcholinesterase inhibitor is a compound as defined in any one of Claims 10 to 16.
19. A wound dressing carrying an acetylcholinesterase inhibitor.
PCT/IB2005/003508 2004-10-12 2005-10-12 Inhibitors of acetylcholinesterase for treating skin diseases WO2006040688A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP05805713A EP1807087A2 (en) 2004-10-12 2005-10-12 Inhibitors of acetylcholinesterase for treating skin diseases
US11/665,280 US9186345B2 (en) 2004-10-12 2005-10-12 Method of treating skin diseases
US14/737,998 US9730919B2 (en) 2004-10-12 2015-06-12 Method of treating skin diseases

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0422634A GB2419093A (en) 2004-10-12 2004-10-12 Acetylcholinesterase inhibitors for the treatment of skin
GB0422634.6 2004-10-12
GB0504202.3 2005-03-01
GB0504202A GB0504202D0 (en) 2005-03-01 2005-03-01 Method of treating skin diseases

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US11/665,280 A-371-Of-International US9186345B2 (en) 2004-10-12 2005-10-12 Method of treating skin diseases
US14/737,998 Division US9730919B2 (en) 2004-10-12 2015-06-12 Method of treating skin diseases

Publications (3)

Publication Number Publication Date
WO2006040688A2 true WO2006040688A2 (en) 2006-04-20
WO2006040688A3 WO2006040688A3 (en) 2006-10-12
WO2006040688B1 WO2006040688B1 (en) 2006-11-23

Family

ID=36148707

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2005/003508 WO2006040688A2 (en) 2004-10-12 2005-10-12 Inhibitors of acetylcholinesterase for treating skin diseases

Country Status (3)

Country Link
US (1) US9186345B2 (en)
EP (2) EP2008660A1 (en)
WO (1) WO2006040688A2 (en)

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008055945A1 (en) 2006-11-09 2008-05-15 Probiodrug Ag 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
WO2008065141A1 (en) 2006-11-30 2008-06-05 Probiodrug Ag Novel inhibitors of glutaminyl cyclase
WO2008104580A1 (en) 2007-03-01 2008-09-04 Probiodrug Ag New use of glutaminyl cyclase inhibitors
WO2010066639A2 (en) * 2008-12-10 2010-06-17 Unilever Plc Skin lightening compositions with acetylcholinesterase inhibitors
WO2011029920A1 (en) 2009-09-11 2011-03-17 Probiodrug Ag Heterocylcic derivatives as inhibitors of glutaminyl cyclase
WO2011100373A1 (en) 2010-02-09 2011-08-18 The Johns Hopkins University Methods and compositions for improving cognitive function
WO2011107530A2 (en) 2010-03-03 2011-09-09 Probiodrug Ag Novel inhibitors
WO2011110613A1 (en) 2010-03-10 2011-09-15 Probiodrug Ag Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5)
WO2011131748A2 (en) 2010-04-21 2011-10-27 Probiodrug Ag Novel inhibitors
WO2012123563A1 (en) 2011-03-16 2012-09-20 Probiodrug Ag Benz imidazole derivatives as inhibitors of glutaminyl cyclase
CN103110627A (en) * 2011-11-16 2013-05-22 高尔医药科技(上海)有限公司 Application of medicinal composition
WO2014144801A1 (en) 2013-03-15 2014-09-18 Agenebio Inc. Methods and compositions for improving cognitive function
EP2865670A1 (en) 2007-04-18 2015-04-29 Probiodrug AG Thiourea derivatives as glutaminyl cyclase inhibitors
EP3030084A4 (en) * 2013-07-29 2016-07-27 Attillaps Holdings ORGANOPHOSPHATES FOR TREATING SKIN CONDITIONS
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
US10159648B2 (en) 2015-05-22 2018-12-25 Agenebio, Inc. Extended release pharmaceutical compositions of levetiracetam
EP3461819A1 (en) 2017-09-29 2019-04-03 Probiodrug AG Inhibitors of glutaminyl cyclase
US10806717B2 (en) 2013-03-15 2020-10-20 The Johns Hopkins University Methods and compositions for improving cognitive function
WO2021189077A1 (en) * 2020-03-18 2021-09-23 Chemistryrx Methods for treating acne
EP3843732A4 (en) * 2018-08-31 2022-05-25 Arctic Therapeutics, LLC Novel topical formulation for intradermal application and uses thereof
US11446241B2 (en) 2013-07-29 2022-09-20 Attillaps Holdings Inc. Treatment of ophthalmological conditions with acetylcholinesterase inhibitors
WO2024151685A1 (en) * 2023-01-09 2024-07-18 Beth Israel Deaconess Medical Center, Inc. Recombinant nucleic acid molecules and their use in wound healing

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010123184A1 (en) * 2009-04-24 2010-10-28 제주대학교 산학협력단 Composition for preventing and treating alopecia disorder containing norgalanthamine compounds as an active ingredient
US20100178307A1 (en) * 2010-01-13 2010-07-15 Jianye Wen Transdermal anti-dementia active agent formulations and methods for using the same
CA2947027A1 (en) * 2014-05-01 2015-11-05 Anterios, Inc. Methods to treat, prevent, and improve skin conditions
PL3157534T3 (en) 2014-06-19 2022-09-12 Attillaps Holdings Acetylcholinesterase inhibitors for treatment of dermatological conditions
US20170232024A1 (en) 2014-08-04 2017-08-17 Jerry Tan Eye Surgery Pte Ltd Pharmaceutical compositions for demodex related blepharitis and eyelid crusting
NZ731850A (en) 2014-11-14 2023-06-30 Follea Int System and method for preventing alopecia
CN107531655B (en) 2015-04-28 2021-03-12 荷兰联合利华有限公司 N-Aralkylcarbonyl-piperazine and N-aralkylcarbonyl-homopiperazine compounds and personal care compositions containing them
MX368097B (en) 2015-04-28 2019-09-19 Unilever Nv N-aralkylcarbonyldiamine compounds and personal care compositions comprising the same.
ES2904543T3 (en) 2015-06-11 2022-04-05 ReJoy Treatment of sexual dysfunction
WO2018093370A1 (en) * 2016-11-17 2018-05-24 Follea International System and method for preventing alopecia
AU2017360346B2 (en) 2016-11-21 2023-11-23 Eirion Therapeutics, Inc. Transdermal delivery of large agents
US11383084B2 (en) * 2017-04-27 2022-07-12 Palo Alto Investors Treatment of dermatological conditions via neuromodulation
CN119174758A (en) 2017-12-15 2024-12-24 塔苏斯制药有限公司 Isoxazoline insect repellent formulations and methods for the treatment of blepharitis
US20210069176A1 (en) * 2018-01-05 2021-03-11 Attillaps Holdings Treating Autoimmune Disorders with Chloroquine and/or Hydroxychloroquine
CN114099490A (en) * 2021-12-30 2022-03-01 温州医科大学附属第二医院（温州医科大学附属育英儿童医院） Function of rivastigmine in preparing medicine for promoting survival of ischemic overlong random skin flap

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5229401A (en) * 1991-09-23 1993-07-20 Hoechst-Roussel Pharmaceuticals Incorporated Substituted pyridinylamino benzo[b]thiophene compounds
DE19626373A1 (en) * 1996-07-02 1998-01-08 Boehringer Ingelheim Kg Novel use of active ingredients that affect the function of non-neuronal acetylcholine
WO1999008672A1 (en) * 1997-08-15 1999-02-25 Shire International Licensing Bv Use of cholinesterase inhibitor for treating diseases associated with proteolytic enzyme activity
WO2000027381A2 (en) * 1998-11-09 2000-05-18 El Khoury George F Topical application of muscarinic agents such as neostigmine for treatment of acne and other inflammatory conditions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI95572C (en) * 1987-06-22 1996-02-26 Eisai Co Ltd Process for the preparation of a medicament useful as a piperidine derivative or its pharmaceutical salt
US5312817A (en) 1991-05-14 1994-05-17 Ernir Snorrason Treatment of fatigue syndrome
GB9606736D0 (en) 1996-02-19 1996-06-05 Shire International Licensing Therapeutic method
US20030124176A1 (en) * 1999-12-16 2003-07-03 Tsung-Min Hsu Transdermal and topical administration of drugs using basic permeation enhancers
US20030195186A1 (en) * 2002-04-10 2003-10-16 University Of Florida Methods of treating medication-, substance-, disease-, and other medical condition-related sexual dysfunction

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5229401A (en) * 1991-09-23 1993-07-20 Hoechst-Roussel Pharmaceuticals Incorporated Substituted pyridinylamino benzo[b]thiophene compounds
DE19626373A1 (en) * 1996-07-02 1998-01-08 Boehringer Ingelheim Kg Novel use of active ingredients that affect the function of non-neuronal acetylcholine
WO1999008672A1 (en) * 1997-08-15 1999-02-25 Shire International Licensing Bv Use of cholinesterase inhibitor for treating diseases associated with proteolytic enzyme activity
WO2000027381A2 (en) * 1998-11-09 2000-05-18 El Khoury George F Topical application of muscarinic agents such as neostigmine for treatment of acne and other inflammatory conditions

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
KOGA M: "VITILIGO A NEW CLASSIFICATION AND THERAPY" BRITISH JOURNAL OF DERMATOLOGY, vol. 97, no. 3, 1977, pages 255-262, XP009067818 ISSN: 0007-0963 *
NGUYEN VU THUONG ET AL: "Pemphigus vulgaris acantholysis ameliorated by cholinergic agonists." ARCHIVES OF DERMATOLOGY. MAR 2004, vol. 140, no. 3, March 2004 (2004-03), pages 327-334, XP009067816 ISSN: 0003-987X *
TINONE G ET AL: "MYASTHENIA GRAVIS AND PSORIASIS A CASE REPORT" JOURNAL OF NEUROIMMUNOLOGY, no. SUPPL. 1, 1991, page 196, XP009067809 & THIRD INTERNATIONAL CONGRESS ON NEUROIMMUNOLOGY, JERUSALEM, ISRAEL, OCTOBER 27-NOVEMBER 1, 1991. J N ISSN: 0165-5728 *
TSCHEN E H ET AL: "CUTANEOUS CYSTICERCOSIS TREATED WITH METRIFONATE" ARCHIVES OF DERMATOLOGY, vol. 117, no. 8, 1981, pages 507-509, XP009067819 ISSN: 0003-987X *

Cited By (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008055945A1 (en) 2006-11-09 2008-05-15 Probiodrug Ag 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
WO2008065141A1 (en) 2006-11-30 2008-06-05 Probiodrug Ag Novel inhibitors of glutaminyl cyclase
EP2481408A2 (en) 2007-03-01 2012-08-01 Probiodrug AG New use of glutaminyl cyclase inhibitors
WO2008104580A1 (en) 2007-03-01 2008-09-04 Probiodrug Ag New use of glutaminyl cyclase inhibitors
EP2865670A1 (en) 2007-04-18 2015-04-29 Probiodrug AG Thiourea derivatives as glutaminyl cyclase inhibitors
WO2010066639A2 (en) * 2008-12-10 2010-06-17 Unilever Plc Skin lightening compositions with acetylcholinesterase inhibitors
WO2010066639A3 (en) * 2008-12-10 2011-01-20 Unilever Plc Skin lightening compositions with acetylcholinesterase inhibitors
CN102245165A (en) * 2008-12-10 2011-11-16 荷兰联合利华有限公司 Skin lightening compositions with acetylcholinesterase inhibitors
WO2011029920A1 (en) 2009-09-11 2011-03-17 Probiodrug Ag Heterocylcic derivatives as inhibitors of glutaminyl cyclase
WO2011100373A1 (en) 2010-02-09 2011-08-18 The Johns Hopkins University Methods and compositions for improving cognitive function
WO2011107530A2 (en) 2010-03-03 2011-09-09 Probiodrug Ag Novel inhibitors
WO2011110613A1 (en) 2010-03-10 2011-09-15 Probiodrug Ag Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5)
WO2011131748A2 (en) 2010-04-21 2011-10-27 Probiodrug Ag Novel inhibitors
WO2012123563A1 (en) 2011-03-16 2012-09-20 Probiodrug Ag Benz imidazole derivatives as inhibitors of glutaminyl cyclase
CN103110627A (en) * 2011-11-16 2013-05-22 高尔医药科技(上海)有限公司 Application of medicinal composition
CN103110627B (en) * 2011-11-16 2016-05-25 高尔医药科技(上海)有限公司 A kind of application of pharmaceutical composition
US10624875B2 (en) 2012-11-14 2020-04-21 The Johns Hopkins University Methods and compositions for treating schizophrenia
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
WO2014144801A1 (en) 2013-03-15 2014-09-18 Agenebio Inc. Methods and compositions for improving cognitive function
US10806717B2 (en) 2013-03-15 2020-10-20 The Johns Hopkins University Methods and compositions for improving cognitive function
US11160785B2 (en) 2013-03-15 2021-11-02 Agenebio Inc. Methods and compositions for improving cognitive function
EP3030084A4 (en) * 2013-07-29 2016-07-27 Attillaps Holdings ORGANOPHOSPHATES FOR TREATING SKIN CONDITIONS
US11446241B2 (en) 2013-07-29 2022-09-20 Attillaps Holdings Inc. Treatment of ophthalmological conditions with acetylcholinesterase inhibitors
US10159648B2 (en) 2015-05-22 2018-12-25 Agenebio, Inc. Extended release pharmaceutical compositions of levetiracetam
US10925834B2 (en) 2015-05-22 2021-02-23 Agenebio, Inc. Extended release pharmaceutical compositions of levetiracetam
EP3461819A1 (en) 2017-09-29 2019-04-03 Probiodrug AG Inhibitors of glutaminyl cyclase
EP3843732A4 (en) * 2018-08-31 2022-05-25 Arctic Therapeutics, LLC Novel topical formulation for intradermal application and uses thereof
WO2021189077A1 (en) * 2020-03-18 2021-09-23 Chemistryrx Methods for treating acne
WO2024151685A1 (en) * 2023-01-09 2024-07-18 Beth Israel Deaconess Medical Center, Inc. Recombinant nucleic acid molecules and their use in wound healing

Also Published As

Publication number Publication date
WO2006040688A3 (en) 2006-10-12
US20070287733A1 (en) 2007-12-13
WO2006040688B1 (en) 2006-11-23
EP2008660A1 (en) 2008-12-31
US9186345B2 (en) 2015-11-17
EP1807087A2 (en) 2007-07-18

Similar Documents

Publication Publication Date Title
US9186345B2 (en) Method of treating skin diseases
US9730919B2 (en) Method of treating skin diseases
US10463681B2 (en) Combination therapy for skin disorders
US5654312A (en) Treatment of inflammatory and/or autoimmune dermatoses with thalidomide alone or in combination with other agents
ES2285733T3 (en) ANTIPRURITIC AGENT.
Tong et al. Postoperative pain control in ambulatory surgery
US5866143A (en) Topical application of opioid drugs such as morphine for relief of itching and skin disease
JP2010511701A (en) Measures for the treatment of acute and chronic diseases of the cerebral circulation, including seizures, based on hydrogenated pyrido (4,3-b) indoles (isomers), pharmacological means based thereon, and for their use Method
JPH11509194A (en) Non-allosteric GABA ▲ lower A ▼ agonist for sleep disorder treatment
US20030181515A1 (en) Methods of using kavalactone compositions
EP0679399B1 (en) Phosphate diesters for treatment of epidermis proliferative diseases
JP2001510157A (en) Peripherally acting anti-pruritus opiates
CA3038544A1 (en) Treatment of prurigo nodularis
MXPA05006771A (en) Ester combination local anesthetic.
US20120122919A1 (en) Pharmaceutical composition combining tenatoprazole and a histamine h2-receptor antagonist
EP3405197B1 (en) Use of delgocitinib for the treatment of chronic hand eczema
JP2002535367A5 (en)
CA2373296C (en) Combination of nicotinic acid or nicotinamide with riboflavin for the treatment of pruritus, itching and inflammation disorders
CN113101289A (en) Application of nicotinamide in preparation of preparation for treating hand-foot skin reaction
US20040014681A1 (en) Method for treating dermatoses and tissue damage
JP2003535897A (en) Novel use of angiotensin II antagonists
CN111065389A (en) Method of treating autoimmune microvascular disease
RU2722396C2 (en) Method of treating palmar-plantar erythrodysesthesia
CA2146607A1 (en) Pharmaceutical composition for treatment of epidermis profilerative disease
EP0988039B1 (en) Topical application of opioid drugs such as morphine for relief of itching and skin disease or irritation

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

NENP Non-entry into the national phase in:

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2005805713

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 11665280

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2005805713

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 11665280

Country of ref document: US

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载